Filing Flows › Opko Health (OPK) › Q3 2026 › vs Q3 2025
Opko Health (OPK) Q3 2026 vs Q3 2025 (year over year)
Opko Health's revenue rose $9.0M (+16%) from $56.4M in Q3 2025 to $65.4M in Q3 2026. The biggest changes: License and Service +$4.9M (+26%); Product +$4.1M (+11%).
Opko Health, Q3 2026: revenue $65.4M (+16% year over year), operating margin -48.0%, net loss $53.5M, operating cash flow −$36.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $41.8M | $37.7M | $4.1M | +11% |
| License and Service | $23.6M | $18.7M | $4.9M | +26% |
| Revenue | $65.4M | $56.4M | $9.0M | +16% |
| Income tax benefit | $7.3M | $8.1M | −$741K | -9% |
| Net loss | $53.5M | −$21.6M | $75.2M | — |
| Costs & expenses | $126M | $112M | $14.6M | +13% |
| Operating costs | $96.8M | $90.0M | $6.8M | +8% |
| Interest & other, net | $29.4M | −$47.1M | $76.6M | — |
| Cost of revenue | $23.4M | $21.4M | $2.0M | +9% |
| Research & development | $32.2M | $29.8M | $2.4M | +8% |
| SG&A | $24.8M | $22.3M | $2.6M | +12% |
| Other operating costs | $16.5M | $16.5M | −$81K | -0.5% |
| Operating cash sources | $61.0M | $60.4M | $655K | +1% |
| Depreciation & amortization | $22.7M | $22.7M | −$12K | -0.1% |
| Share-based compensation | $2.0M | $3.0M | −$1.0M | -33% |
| Cash used in operations | $36.3M | $34.6M | $1.7M | +5% |
| Net loss absorbed | $53.5M | −$21.6M | $75.2M | — |
| Working capital & other | $7.5M | $82.0M | −$74.5M | -91% |
Questions
How much did Opko Health's revenue grow year over year in Q3 2026?
Opko Health's revenue rose $9.0M (+16%) from $56.4M in Q3 2025 to $65.4M in Q3 2026.
What drove Opko Health's revenue change in Q3 2026?
License and Service +$4.9M (+26%); Product +$4.1M (+11%).